QBKPN
Phase 2Biologic
QBKPN is one of 61 biologic programs targeting Respiratory tract infection. It is currently in Phase 2.
2
Indications
3
Total Trials
1
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Lenvima
EisaiPreclinical
Gilotrif
Boehringer IngelheimPreclinical
Ofev
Boehringer IngelheimPreclinical
QBKPN
QQu Biologics Inc.
Phase 2
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
REGN2810
RegeneronPreclinical
Immune Checkpoint Inhibitors
PPeking Union Medical College Hospital
Preclinical
Neoadjuvant Immunotherapy
RRenJi Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Respiratory tract infection1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for QBKPN. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- QQu Biologics Inc.